|Other Names||Cytochrome P450 1A1, CYPIA1, Cytochrome P450 form 6, Cytochrome P450-C, Cytochrome P450-P1, CYP1A1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7993c was selected from the C-term region of human CYP1A1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.|
|Cellular Location||Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein|
|Tissue Location||Lung, lymphocytes and placenta.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CYP1A1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. The enzyme's endogenous substrate is unknown; however, it is able to metabolize some PAHs to carcinogenic intermediates. CYP1A1 gene has been associated with lung cancer risk.
Delpisheh,A., Eur. J. Obstet. Gynecol. Reprod. Biol. 143 (1), 38-42 (2009)Zhuo,W., Cancer Invest. 27 (1), 86-95 (2009)
If you have any additional inquiries please email technical services at email@example.com.